Edgewise Therapeutics, Inc. EWTX 深 滬
等待開盤 08-19 09:30:00 美东时间
14.00
-0.150
-1.06%
華盛通- 最 高14.49
- 今 開14.27
- 成交量 50.17万股
- 最 低 13.91
- 昨 收 14.15
- 總市值 14.70亿
- 52周最高 38.12
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 10.60
- 委 比 -64.09%
- 總股本 1.05亿
- 歷史最高 40.49
- 量 比 0.77
- 振 幅 4.10%
- 歷史最低 5.12
- 每 手 1
- 風險率 7.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Analysts’ Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-12 18:20
美股机会日报丨逼近历史高点！比特币突破12万美元大关；花旗看多标普500指数目标价至6600点
逼近历史高点！比特币突破12万美元大关，美股加密货币概念普涨；花旗看多标普500指数目标价至6600点；AMC院线盘前大涨近10%，公司Q2财报大超预期>>
08-11 20:37
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $49
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $49.
08-09 01:44
Edgewise Therapeutics GAAP EPS of -$0.34
Edgewise Therapeutics press release (NASDAQ:EWTX): Q2 GAAP EPS of -$0.34. Cash, cash equivalents and marketable securities were approximately $594.0 million as of June 30, 2025. More on Edgewise The...
08-07 21:17
Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.43) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.43) by 20.19 percent. This is unchanged from the same period last year.
08-07 20:11
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel th...
08-07 04:02
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
Edgewise falls after data for muscular dystrophy therapy
Edgewise Therapeutics (NASDAQ:EWTX) lost ~9% in the morning hours on Thursday after the company posted data from clinical trials for its lead asset, sevasemten, against Becker and Duchenne muscular dy...
06-26 22:20
Edgewise Therapeutics Reports Results in Sevasemten Program for Becker and Duchenne Muscular Dystrophies
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten program for Becker and Duchenne muscular dystrophies. The Company
06-26 18:04
